Information Library

Results for: Cost control/reduction - Flexible outsourcing

In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions.  Search our library today.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • QUINTILES AND MOVETIS ANNOUNCE STRATEGIC ALLIANCE

    Press Release — January 28, 2010 - Quintiles announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany.

  • How to Navigate the New CDISC Standard

    Brochure — March 25, 2009
    Quintiles – a CDISC Registered Solutions Provider – helps you get every detail right.

  • Maneuvering a Drifting Project Back on Course

    Case Study — March 25, 2009
    The NDA had been drifting within the FDA for years, and now it was subject to intense scrutiny by two agency reviewers.

  • Geoff Garabedian

    Hear from the Experts — March 25, 2009
    As Practice Leader for Regulatory and Quality in the U.S., Geoff combines a strong management consulting background with specific experience in the regulatory and compliance arena, including design and implementation of large-scale process, organization and technology transformations.

  • Jim Featherstone, Ph.D.

    Hear from the Experts — March 25, 2009
    Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice.

  • Matthew Eberhart

    Hear from the Experts — March 25, 2009
    Matt is a proven business-building executive with a strong track record of implementing successful business development initiatives for consulting healthcare companies in both North America and Europe.

  • Antibiotic Safety Assessment

    Case Study — March 25, 2009
    A major pharmaceutical company presented Quintiles with a pressing challenge – to collect extensive amounts of Phase IV data in compressed time windows because the treatment conditions were subject to seasonal variants.

  • Podcast: A New Gold Standard

    Hear from the Experts — May 1, 2008
    John Doyle discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.

Page 2 of 2 (18 results)

Subscribe to Email Based on Your Interests

Set preferences